Filing Details

Accession Number:
0001209191-24-000071
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-02 16:07:46
Reporting Period:
2023-12-29
Accepted Time:
2024-01-02 16:07:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1515673 Ultragenyx Pharmaceutical Inc. RARE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1248093 D Emil Kakkis C/O Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato CA 94949
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-12-29 30,000 $47.87 569,770 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 2,263,985 Indirect By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 200
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.54 to $48.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. Includes 27 shares acquired under the Company's Amended and Restated 2014 Employee Stock Purchase Plan on October 31, 2023.
  4. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.